Tab. III.
Basic characteristics of group B, by survival and death
| Group B | Survival (N = 78) |
Death (N = 31) |
P |
|---|---|---|---|
| Age [years] | 44.8 ± 11.4 | 51.3 ± 11.6 | 0.02 |
| HF duration [months] | 14.5 (7-42) | 48 (12-60) | 0.03 |
| NYHA class | 2 (2-2) | 2.5 (2-3) | < 0.001 |
| Diabetes | 3 (3.8%) | 9 (29%) | < 0.001 |
| LVEF [%] | 27.8 ± 6.9 | 23.2 ± 6.7 | 0.003 |
| RVEDd [mm] | 29.0 ± 4.9 | 32.5 ± 5.4 | 0.005 |
| hs-CRP [mg/l] | 1.12 (0.74-2.68) | 3.08 (1.22-5.6) | 0.04 |
| NT-proBNP [pg/ml] | 745.8 (395.9-1342.5) | 2067.5 (1116.5-3880.5) | < 0.001 |
| eGFR [ml/min/1.73 m2] | 96.3 ± 18.5 | 84.2 ± 26.8 | 0.03 |
| Uric acid [µmol/l] | 418.7 ± 112.3 | 489.5 ± 140 | 0.03 |
| Bilirubin [µmol/l] | 16.6 (11.5-21.5) | 18.5 (14.3-28.8) | 0.049 |
eGFR – estimated glomerular filtration rate, hs-CRP – high-sensitivity C-reactive protein, LVEF – left ventricular ejection fraction, NT-proBNP – N-terminal propeptide of the brain natriuretic peptide, NYHA – New York Heart Association, RVEDd – right ventricular end-diastolic diameter M-mode (diastole)